June 13, 2022
Before we begin today a quick note to anyone who freaked looking at shares of Dexcom, no the company was not accused of a nefarious dealing just a four for one stock split. Still, it was somewhat of a shock seeing shares at $70 after seeing them well over $600 not that long ago. With G7 approval coming, the launch of the Omnipod 5 and the general growth in CGM we’d say that in the midst of a very bad market this just might be a great time to get in. Just saying.
Now onto the business at hand . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.